Pericarditis resident survival guide
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mugilan Poongkunran M.B.B.S [2]
Overview
Acute pericarditis refers to inflammation of the pericardial sac, which can be dry, fibrinous or effusive, independent from its aetiology. The term myopericarditis, or perimyocarditis, is used for cases of acute pericarditis that also demonstrate myocardial inflammation resulting in global or regional myocardial dysfunction, elevations of troponins, MB creatine-kinase, myoglobin and tumour necrosis factor.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
- Autoimmune: Rheumatoid arthritis, Sjögren’s syndrome, SLE, systemic sclerosis, systemic vasculitis
- Bacterial: Coxiella burnetii, pneumococcus, staphylococcus, streptococcus, tuberculosis
- Cardiovascular: Dressler's syndrome, post-myocardial infarction syndrome, postpericardiotomy syndrome, posttraumatic pericarditis
- Neoplastic: Breast cancer, leukemia, lung cancer, lymphoma
- Viral: Adeno virus, CMV, coxsackie, EBV, echovirus, HBV, HCV, HIV, HIV, human herpes virus 6, influenza, mumps, parvovirus B19, rubella, varicella
- Metabolic: Myxedema, uremia
Management
The following is an algorithm depicting the management of acute pericarditis in adults.[1][2][3]
Characterize the Clinical, EKG and imaging findings ❑ Characteristic chest pain
❑ Suggestive EKG changes
❑ Suggestive echocardiography changes
| |||||||||||||||||||||||||||||||||||||||||||||||||
Consider a possible diagnosis of acute pericarditis | |||||||||||||||||||||||||||||||||||||||||||||||||
Characterize the symptoms: Symptoms suggestive of pericarditis:
Symptoms associated with pericardial effusion:
❑ With a hemodynamically significant pericardial effusion
Other associated symptoms: Obtain a detailed history:
❑ Medications ❑ Systemic illness ❑ Others
| |||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient: ❑ Vitals
❑ Cardiovascular:
{{#ev:youtube|watch?v=EUCp_3_vwtw}}
❑ Respiratory system:
❑ Abdominal examination
| |||||||||||||||||||||||||||||||||||||||||||||||||
Order laboratory tests (urgent): ❑ CBC: Leucocytosis Order electrocardiogram (urgent): ❑ Typical findings in pericarditis
❑ Electrical alternans (in cardiac tamponade) Order imaging (urgent):
| |||||||||||||||||||||||||||||||||||||||||||||||||
Diagnosis of acute pericarditis: Atleast two of the following criteria: | |||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No or equivocal | ||||||||||||||||||||||||||||||||||||||||||||||||
❑ Acute pericarditis ❑ Myopericarditis * Elevated cardiac enzymes * Global or focal myocardial dysfunction on echo | Consider cardiac MRI (CMR) | Consider alternative diagnosis and treat accordingly | |||||||||||||||||||||||||||||||||||||||||||||||
Treat as acute pericarditis or myopericarditis if there is delayed enhancement on CMR | |||||||||||||||||||||||||||||||||||||||||||||||||
High risk features ❑ Fever >38°C | |||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||
Inpatient treatment | Outpatient treatment | ||||||||||||||||||||||||||||||||||||||||||||||||
Stable | Unstable | No pre-existing coronary artery disease | Pre-existing coronary artery disease | ||||||||||||||||||||||||||||||||||||||||||||||
❑ NSAID's or aspirin ❑ Colchicine may be used in recurrent or refractory disease ❑Clinical testing for underlying etiology | High risk features ❑ Immediately transfer the patient to ICU ❑ Colchicine | NSAID's ❑ Indomethacin:
❑ Ibuprofen:
❑ Add gastroprotective agents
Colchicine ❑ Alone or in combination with NSAIDs Steroids ❑ Avoid steroids to treat an initial episode of pericarditis | Aspirin
❑ Add gastroprotective agents
❑ Stop anticoagulants if patient develops pericardial effusion Steroids ❑ Avoid steroids to treat an initial episode of pericarditis | ||||||||||||||||||||||||||||||||||||||||||||||
Response to Rx | |||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||
Follow up ❑ 7 to 10 days to assess response to treatment | Hospital admission ❑ Indication that the underlying cause may not be viral or idiopathic in nature. | ||||||||||||||||||||||||||||||||||||||||||||||||
Etiology Specific Management
Clinical subgroups | Specific investigations | Treatment |
---|---|---|
Viral pericarditis | ❑ Diagnostic pericardiocentesis :❑ PCR or in-situ hybridisation |
❑ CMV pericarditis :❑ Hyperimmunoglobulin OD 4 ml/kg on day 0, 4,and 8; 2 ml/kg on day 12 and 16. ❑ Coxsackie B pericarditis :❑ Interferon alpha or beta 2,5 Mio. IU/m2 surface area s.c. 3 x per week ❑ Adenovirus and parvovirus B19 perimyocarditis :❑ Immunoglobulin 10 g IV at day 1 and 3 for 6-8 hours |
Bacterial pericarditis | ❑ Diagnostic pericardiocentesis :❑ Gram stain, acid fast stain, fungal stain, and cultures of the pericardial fluid :❑ Protein, glucose and cell count ❑ Gram stain, acid fast stain, fungal stain, and cultures of other body fluids |
❑ Therapeutic pericardiocentesis or pericardial window ❑ Pericardiectomy may be used in treatment of recurrent pericardial efussion and in patients with dense adhesions, loculated and thick purulent effusion ❑ Antimicrobial therapy :❑ Intiate antistaphylococcal antibiotic plus aminoglycoside, followed by tailored antibiotic therapy according to pericardial fluid and blood cultures :❑ Empiric regimen can be started for the following ::❑ Immunosuppression ::❑ Concurrent infection at another body site ::❑ Presence of intravascular lines or prosthetic devices ::❑ Recent antimicrobial therapy ❑ Antifungal therapy |
Tuberculous pericarditis | ❑ CT scan and/or MRI of the chest ❑ Culture of sputum, gastric aspirate, and/or urine ❑ Diagnostic pericardiocentesis in all suspected tuberculous pericarditis patients :❑ PCR of pericardial fluid :❑ High adenosine deaminase activity and interferon gamma concentration in pericardial effusion ❑ Pericardial biopsy (rapid diagnosis) ❑ Tuberculin skin test (not helpful) ❑ Enzyme-linked immunospot (ELISPOT) ❑ Serum titres of antimyolemmal and antimyosin antibodies |
❑Anti-tuberculosis chemotherapy :❑ Emperic therapy in TB endemic areas and in cases with high clinical suspicion ❑ Pericardiectomy is warranted in the setting of persistent constrictive pericarditis or when no general improvement after 4-8 weeks following antituberculosis chemotherapy ❑ Prednisone can be used. |
Neoplastic pericarditis | ❑ CT scan and/or MRI of the chest ❑ Diagnostic pericardiocentesis ❑ Pericardial biopsy |
❑ Systemic antineoplastic treatment ❑ Assess the life expectancy of the patients before proceeding with the treatment :❑ Better prognosis patients should be treated more aggressively :❑ Advanced malignancy should be treated palliatively with pericardiocentesis :❑ Recurrence of pericardial effusion is prevented using any of the following techniques ::❑ Prolonged pericardiocentesis ::❑ Pericardial sclerosis ::❑ Pericardiotomy ::❑ Intrapericardial chemotherapy |
Pericarditis in renal failure | ❑ Renal function test ❑ Diagnostic pericardiocentesis ❑ Pericardial biopsy |
❑ Uremic pericarditis :❑ Hemodialysis or peritoneal dialysis :❑ Heparin-free haemodialysis should be used ❑ Dialysis-associated pericarditis :❑ Pericardiocentesis for large effusion :❑ Pericardiotomy in non resolving effusion |
Do's
Dont's
References
- ↑ Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y; et al. (2004). "Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology". Eur Heart J. 25 (7): 587–610. doi:10.1016/j.ehj.2004.02.002. PMID 15120056.
- ↑ Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B; et al. (2013). "American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography". J Am Soc Echocardiogr. 26 (9): 965–1012.e15. doi:10.1016/j.echo.2013.06.023. PMID 23998693.
- ↑ Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y (2010). "Controversial issues in the management of pericardial diseases". Circulation. 121 (7): 916–28. doi:10.1161/CIRCULATIONAHA.108.844753. PMID 20177006.